CTRI/2020/06/026173已完成3 期
A Pre-clinical and Clinical study to Evaluate the Efficacy of Arjuna Ksheerapaka Churna in the Management of Medoroga w.s.r. to Dyslipidemia
RGGPG Ayurvedic College0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a) Diagnosed and confirmed cases of dyslipidemia on the basis of investigations.
- •b) Patient between the age group of 20-70 years of either sex who will fulfill the criteria of diagnosis.
排除标准
- •a) Patient not willing for the trial.
- •b) Patients suffering from major systemic illness necessitating long term treatment (R.A., PTB, malignancy).
- •c) Poorly controlled hypertensive patients (SBP ââ?°Â¥ 140 mm of Hg and/or DSB ââ?°Â¥ 90 mm of Hg).
- •d) Patient having past history of MI and unstable angina.
- •e) Patients having concomitant disorders like ischemic heart disease, congestive heart failure, acute renal failure, chronic renal failure etc.
- •f) Patients below 20 years and above 70 years of age.
- •g) Patients who are participating in any other clinical trial or have completed participation during the past three months.
- •h) Any condition which the investigator thinks may compromise with the safety of the subject.
研究者
相似试验
尚未招募
不适用
To study the efficacy ofAshwagandhadi Avaleha as an Adjuvant with Anti Tubercular Treatment.CTRI/2021/05/033863Principal
已完成
1 期
An Experimental and clinical trial to study the effect of Triphala RasayanaCTRI/2020/07/026483RGGPG Ayurvedic College and Hospital Paprola28
尚未招募
1 期
Study to evaluate the effect of Suvarnaprashan yoga on growth and development in ChildreCTRI/2023/05/052262RGGPG Ayurvedic College
尚未招募
不适用
A study conducted in outside human body to evaluate the Efficacy of a type of Cells Manufactured from Healthy Volunteers and Patients with Relapsed/ Refractory Acute Lymphoblastic Leukemia (a type of blood cancer) in laboratory settingCTRI/2016/12/007517TMC Research Administration Council20
尚未招募
不适用
Efficacy of Neelkanthi churna in Madhumeha w.s.r to Type 2 Diabetes MellitusCTRI/2021/06/034030Principal
